Kancera

Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

CEO statement

“Kancera is a world leading pioneer in the field of small molecule CX3CR1 antagonists. This is now manifested with our candidate drugs rugocrixan and fosrugocrixan setting the name standard for this new class of drugs.”

Peter Selin, CEO Kancera

Press Releases

2025-06-16
Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145
2025-06-13
Kancera reports positive top-line results from the KANDOVA study
2025-06-05
Kancera reports positive outcome of pre-IND meeting with FDA

Events

No upcoming events are currently in the calendar

Presentations

Presentation of Kancera’s 2025 Q1 Interim Report (in Swedish)